Sensei Biotherapeutics

Company snapshot

Sentinel BioTherapeutics is a Houston-based clinical-stage biotech company developing localized immunotherapies that safely activate the immune system against solid tumors.

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sensei Biotherapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Sensei Biotherapeutics.

1. May 23, 2026 Clinical update

   SNS-301 — Phase 2

2. May 23, 2026 Clinical update

   SNS-301 — Phase 2

3. May 23, 2026 Clinical update

   PAN-301-1 — Phase 1

4. Mar 19, 2024 Patent grant

   Modified antibodies and related compounds, compositions and methods of use

View all clinical trial activity →

• What is Sensei Biotherapeutics?

  Sentinel BioTherapeutics is a pharma organization headquartered in ROCKVILLE, MD, USA. It trades on NYSE under ticker SNSE. Primary therapeutic focus areas include Prostate Cancer, Myelodysplastic Syndromes, Squamous Cell Carcinoma of the Head and Neck. NovaPharmaNews links 3 cli

• Is Sensei Biotherapeutics publicly traded?

  Yes. Sensei Biotherapeutics is listed with ticker SNSE on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Sensei Biotherapeutics develop or market?

  No drug profiles are currently linked to Sensei Biotherapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Sensei Biotherapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sensei Biotherapeutics focus on?

  Sensei Biotherapeutics focuses on Prostate Cancer, Myelodysplastic Syndromes, Squamous Cell Carcinoma of the Head and Neck based on our analysis of their pipeline programs and drug development activities.